Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine

Canadian Journal of Public Health

Volumn 99, Issue 1, 2008, Pages 57-61

  Winters, Meghan ^a   Patrick, David M ^a,b   Marra, Fawziah ^b   Buxton, Jane ^a,b   Chong, Mei ^b   Isaac Renton, Judith L ^a,b   Shaw, Carol ^b   Tyrrell, Gregory J ^c   Lovgren, Marguerite ^c   Paulus, Stephane ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c National Centre for Streptococcus   (Canada)

^d BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Antimicrobial drug resistance; Canada; Pneumococcal infections; Pneumococcal vaccines

Indexed keywords

EID: 38949193215     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03403742     Document Type: Article

References (26)

1. WHO. Overcoming antimicrobial resistance. World Health Organization, 2000. Available online at: http://www.who.int/infectious-disease-report/ 2000/index.html (Accessed October 20, 2005).
2. Cizman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents 2003;21:297-307.
3. Goossens H, Sprenger M. Community acquired infections and bacterial resistance. BMJ 1998;317:654-57.
4. Conly J. Antimicrobial resistance in Canada. CMAJ 2002;167:885-91.
5. Powis J, McGeer A, Green K, Vanderkooi O, Weiss K, Zhanel G, et al. In vitro antimicrobial susceptibilities of streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004;48:3305-11.
6. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24.
7. National Advisory Committee on Immunization. Statement on recommended use of pneumococcal conjugate vaccine. CCDR 2002;28 (ACS-2).
8. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-39.
9. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Results of the Canadian Respiratory Organism Susceptibility study, 1997 to 2002. AAC 2003;47:1867-74.
10. Paulus S, David ST, Tang W, Winters M, Buxton J, Henry B, et al. Incidence of invasive pneumococcal disease after the introduction of the universal immunization programme in B.C. (2002-2005). CCDR 2006;32:157-61.
11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. Document standard M100-14. In: National Committee for Clinical Laboratory Standards, Wayne, PA, 2004.
12. BC STATS, BC Ministry of Labour and Citizens Services and Health Data Warehouse. Population Extrapolation for Organizational Planning with Less Error (P.E.O.P.L.E.), 2005.
13. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
14. Stephens D, Zughaier S, Whitney C, Baughman WS, Barker L, Gay K, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: Population-based assessment. Lancet 2005;365:855-63.
15. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63.
16. Centre for Disease Control. National Immunization Survey, 2005 data. Available online at: http://www2a.cdc.gov/nip/coverage/nis/ nis_iap.asp?fmt=v&rpt=tab09_24mo_iap&qtr=Q1/2005-Q4/2005 (Accessed March 15, 2007).
17. Centre for Disease Control. Early Release of Selected Estimates Based on Data From the January-March 2006 National Health Interview Survey. Available online at: http://www.cdc.gov/nchs/data/nhis/earlyrelease/ 200609_05.pdf (Accessed March 15, 2007).
18. BC Centre for Disease Control. Performance measure 32: Two-year olds with up-to-date immunizations. 2005 cycle. Vancouver, BC, 2006.
19. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-39.
20. Canadian Bacterial Surveillance Network. Trends in Antimicrobial Resistance in Streptococcus pneumoniae - Canada. Available online at: http://microbiology.mtsinai.on.ca/data/sp/spn_can.shtml (Accessed April 26, 2006).
21. Canadian Bacterial Surveillance Network. Trends in Antimicrobial Resistance in Streptococcus pneumoniae - British Columbia. Available online at: http://microbiology.mtsinai.on.ca/data/sp/sp_bc.shtml (Accessed April 26, 2006).
22. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005;5:83-93.
23. File TM, Jr. Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern. Am J Med 2004; 117(Suppl 3A):39S-50S.
24. Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: It's all relative. Clin Infect Dis 2004;38:99-103.
25. Lynch IJ, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002;34(Suppl 1):S27-S46.
26. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: Does in vitro resistance really matter? Clin Infect Dis 2006;42:224-33.